risperidone has been researched along with Hypertension in 7 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
Hypertension: Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Experiment 1: Wistar-Kyoto (WKY) rats, spontaneously hypertensive rats (SHRs) and stroke-prone SHRs (SHR-SPs) were treated with risperidone (0." | 7.78 | Risperidone enhances the vulnerability to stroke in hypertensive rats. ( Godfraind, T; Liu, C; Song, SW; Su, BL; Su, DF; Sun, Y; Yang, C, 2012) |
| "Risperidone has a relatively low risk of causing obesity and diabetes mellitus and is a first-line treatment for schizophrenia." | 7.74 | Glucose and lipid metabolism of long-term risperidone monotherapy in patients with schizophrenia. ( Hosoda, H; Inoue, T; Itoh, K; Izumi, T; Kangawa, K; Koyama, T; Kusumi, I; Murashita, M; Nakagawa, S; Tanaka, T, 2007) |
| "Our data show a potential pharmacokinetic interaction, most likely via CYP3A4 between amlodipine and RIS, reflected in significantly different C/Ds for RIS, 9-OH-RIS and AM." | 5.43 | Pharmacokinetic considerations in the treatment of hypertension in risperidone-medicated patients - thinking of clinically relevant CYP2D6 interactions. ( Gründer, G; Haen, E; Lammertz, SE; Paulzen, M; Schoretsanitis, G; Schruers, KR; Stegmann, B; Walther, S, 2016) |
| "Posterior reversible cerebral edema syndrome is a generally reversible neurologic condition that is diagnosed based on distinctive clinical and radiologic findings." | 5.40 | Arterial hypertension and posterior reversible cerebral edema syndrome induced by risperidone. ( Agostoni, C; Bianchetti, MG; Fossali, EF; Mauri, MC; Mazzoni, MB; Milani, GP; Triulzi, F, 2014) |
| "Experiment 1: Wistar-Kyoto (WKY) rats, spontaneously hypertensive rats (SHRs) and stroke-prone SHRs (SHR-SPs) were treated with risperidone (0." | 3.78 | Risperidone enhances the vulnerability to stroke in hypertensive rats. ( Godfraind, T; Liu, C; Song, SW; Su, BL; Su, DF; Sun, Y; Yang, C, 2012) |
| "Risperidone has a relatively low risk of causing obesity and diabetes mellitus and is a first-line treatment for schizophrenia." | 3.74 | Glucose and lipid metabolism of long-term risperidone monotherapy in patients with schizophrenia. ( Hosoda, H; Inoue, T; Itoh, K; Izumi, T; Kangawa, K; Koyama, T; Kusumi, I; Murashita, M; Nakagawa, S; Tanaka, T, 2007) |
| "Our data show a potential pharmacokinetic interaction, most likely via CYP3A4 between amlodipine and RIS, reflected in significantly different C/Ds for RIS, 9-OH-RIS and AM." | 1.43 | Pharmacokinetic considerations in the treatment of hypertension in risperidone-medicated patients - thinking of clinically relevant CYP2D6 interactions. ( Gründer, G; Haen, E; Lammertz, SE; Paulzen, M; Schoretsanitis, G; Schruers, KR; Stegmann, B; Walther, S, 2016) |
| "Data for 60,162 subjects with type 1 diabetes up to the age of 25 years registered in the nationwide German/Austrian Diabetes Survey were included in the analysis." | 1.42 | Comparison of glycemic and metabolic control in youth with type 1 diabetes with and without antipsychotic medication: analysis from the nationwide German/Austrian Diabetes Survey (DPV). ( Bartus, B; Bollow, E; Galler, A; Haberland, H; Holl, RW; Meusers, M; Näke, A; Schober, E, 2015) |
| "Posterior reversible cerebral edema syndrome is a generally reversible neurologic condition that is diagnosed based on distinctive clinical and radiologic findings." | 1.40 | Arterial hypertension and posterior reversible cerebral edema syndrome induced by risperidone. ( Agostoni, C; Bianchetti, MG; Fossali, EF; Mauri, MC; Mazzoni, MB; Milani, GP; Triulzi, F, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Milani, GP | 1 |
| Bianchetti, MG | 1 |
| Mazzoni, MB | 1 |
| Triulzi, F | 1 |
| Mauri, MC | 1 |
| Agostoni, C | 1 |
| Fossali, EF | 1 |
| Godman, B | 1 |
| Petzold, M | 1 |
| Bennett, K | 1 |
| Bennie, M | 1 |
| Bucsics, A | 1 |
| Finlayson, AE | 1 |
| Martin, A | 1 |
| Persson, M | 1 |
| Piessnegger, J | 1 |
| Raschi, E | 1 |
| Simoens, S | 1 |
| Zara, C | 1 |
| Barbui, C | 1 |
| Galler, A | 1 |
| Bollow, E | 1 |
| Meusers, M | 1 |
| Bartus, B | 1 |
| Näke, A | 1 |
| Haberland, H | 1 |
| Schober, E | 1 |
| Holl, RW | 1 |
| Paulzen, M | 1 |
| Haen, E | 1 |
| Gründer, G | 1 |
| Lammertz, SE | 1 |
| Stegmann, B | 1 |
| Schruers, KR | 1 |
| Walther, S | 1 |
| Schoretsanitis, G | 1 |
| Clark, D | 1 |
| Skrobot, OA | 1 |
| Adebiyi, I | 1 |
| Susce, MT | 1 |
| de Leon, J | 1 |
| Blakemore, AF | 1 |
| Arranz, MJ | 1 |
| Song, SW | 1 |
| Sun, Y | 1 |
| Su, BL | 1 |
| Liu, C | 1 |
| Yang, C | 1 |
| Godfraind, T | 1 |
| Su, DF | 1 |
| Murashita, M | 1 |
| Inoue, T | 1 |
| Kusumi, I | 1 |
| Nakagawa, S | 1 |
| Itoh, K | 1 |
| Tanaka, T | 1 |
| Izumi, T | 1 |
| Hosoda, H | 1 |
| Kangawa, K | 1 |
| Koyama, T | 1 |
7 other studies available for risperidone and Hypertension
| Article | Year |
|---|---|
Arterial hypertension and posterior reversible cerebral edema syndrome induced by risperidone.
Topics: Antipsychotic Agents; Brain Edema; Child; Female; Humans; Hypertension; Risperidone | 2014 |
Can authorities appreciably enhance the prescribing of oral generic risperidone to conserve resources? Findings from across Europe and their implications.
Topics: Adult; Antipsychotic Agents; Drug Prescriptions; Drugs, Generic; Europe; Health Resources; Humans; H | 2014 |
Comparison of glycemic and metabolic control in youth with type 1 diabetes with and without antipsychotic medication: analysis from the nationwide German/Austrian Diabetes Survey (DPV).
Topics: Adolescent; Adult; Albuminuria; Antipsychotic Agents; Blood Glucose; Body Mass Index; Diabetes Compl | 2015 |
Pharmacokinetic considerations in the treatment of hypertension in risperidone-medicated patients - thinking of clinically relevant CYP2D6 interactions.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Antipsychotic Agent | 2016 |
Apolipoprotein-E gene variants associated with cardiovascular risk factors in antipsychotic recipients.
Topics: Alleles; Antipsychotic Agents; Apolipoproteins E; Body Mass Index; Cardiovascular Diseases; Diabetes | 2009 |
Risperidone enhances the vulnerability to stroke in hypertensive rats.
Topics: Animals; Apoptosis; Cells, Cultured; Hypertension; Neurons; Rats; Rats, Inbred SHR; Rats, Inbred WKY | 2012 |
Glucose and lipid metabolism of long-term risperidone monotherapy in patients with schizophrenia.
Topics: Adiponectin; Adult; Antipsychotic Agents; Body Composition; Body Mass Index; Cholesterol, HDL; Femal | 2007 |